Your browser doesn't support javascript.
loading
Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (Macaca mulatta).
Bhatt, Laxit K; Shah, Chitrang R; Patel, Rajesh J; Patel, Shital D; Patel, Sudhir R; Patel, Vipul A; Patel, Jitendra H; Dwivedi, Pankaj; Shah, Niraj A; Sundar, Rajesh S; Jain, Mukul R.
Afiliação
  • Bhatt LK; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Shah CR; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Patel RJ; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Patel SD; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Patel SR; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Patel VA; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Patel JH; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Dwivedi P; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Shah NA; Animal Research Facility, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Sundar RS; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
  • Jain MR; Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Ahmedabad, India.
Toxicol Mech Methods ; 33(6): 490-501, 2023 Nov.
Article em En | MEDLINE | ID: mdl-36879461
Rhesus monkeys are a non-rodent species employed in the preclinical safety evaluation of pharmaceuticals and biologics. These nonhuman primate species have been increasingly used in biomedical research because of the similarity in their ionic mechanisms of repolarization with humans. Heart rate and QT interval are two primary endpoints in determining the pro-arrhythmic risk of drugs. As heart rate and QT interval have an inverse relationship, any change in heart rate causes a subsequent change in QT interval. This warrants for calculation of a corrected QT interval. This study aimed to identify an appropriate formula that best corrected QT for change in heart rate. We employed seven formulas based on source-species type, clinical relevance, and requirements of various international regulatory guidelines. Data showed that corrected QT interval values varied drastically for different correction formulas. Equations were compared on their slope values based on QTc versus RR plots. The rank order of the slope for different formulas was (closest to farthest from zero) QTcNAK, QTcHAS, QTcBZT, QTcFRD, QTcVDW, QTcHDG, and QTcFRM. QTcNAK emerged to be the best correcting formula in this study. It showed the least correlation with the RR interval (r = -0.01) and displayed no significant difference amongst the sexes. As there is no universally recognized formula for preclinical use, the authors recommend developing a best-case scenario model for specific study designs and individual organizations. The data from this research will be helpful in deciding an appropriate QT correction formula for the safety assessment of new pharmaceuticals and biologics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article